Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gynecologic Cancers
•
Cervical Cancer
How do you think the BEATcc trial will change management of patients with advanced or recurrent cervical cancer?
Are you ready to start using atezolizumab?
Related Questions
Given the results of KEYNOTE-A18, do you plan to recommend adding pembrolizumab to primary chemoradiotherapy for advanced stage cervical cancer?
In light of the SHAPE trial results, how would you manage a patient with an incidentally diagnosed FIGO IA1 cervical cancer after simple extrafascial hysterectomy/BSO?
Do you have a BMI cutoff for abdominal radical hysterectomy for cervical cancer?
What brachytherapy regimen would you use for a patient who completed only the EBRT portion of their planned definitive chemoradiation course for locally advanced cervical cancer, who is now presenting with persistent/recurrent local disease?
Do you recommend progesterone for endometrial protection in a young woman on estrogen replacement therapy for iatrogenic menopause after definitive radiation therapy for locally advanced cervical cancer?
What are your top takeaways in Gynecologic Cancers from ASCO 2023?
In a patient with prior LEEP and no residual cervix found to have HSIL on ECC, what type of hysterectomy would you offer?
Do you utilize GCSF during pelvic chemoradiation therapy for cervical cancer or avoid it due to concern for paradoxical neutropenia from concomitant radiation + GCSF?
How do you manage a patient with cervical cancer who has FDG uptake in bilateral ischial tuberosities with lytic areas on CT correlate, and also has a history suspicious for untreated polymyalgia rheumatica with chronic symptoms in the same anatomic locations?
What is your approach to lymph node evaluation in patients undergoing radical hysterectomy for early cervical cancer?